Mosapride citrate
[CAS# 112885-42-4]

Identification

• Classification: Biochemical >> Inhibitor >> Neuronal signaling >> 5-HT receptor agonist
• Name: Mosapride citrate
• Synonyms: 4-Amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]-2-morpholinyl]methyl]-benzamide 2-hydroxy-1,2,3-propanetricarboxylate; Gasmotin
• Molecular Formula: C₂₁H₂₅ClFN₃O₃.C₆H₈O₇;C₂₇H₃₃ClFN₃O₁₀
• Molecular Weight: 614.02
• CAS Registry Number: 112885-42-4
• EC Number: 601-211-6
• SMILES: CCOC1=CC(=C(C=C1C(=O)NCC2CN(CCO2)CC3=CC=C(C=C3)F)Cl)N.C(C(=O)O)C(CC(=O)O)(C(=O)O)O

Properties

• Solubility: 90 mg/mL (DMSO)

Safety Data

• Hazard Symbols: GHS08 Warning
• Risk Statements: H361
• Safety Statements: P203-P280-P318-P405-P501

Hazard Classification

Hazard	Class	Category Code	Hazard Statement
Reproductive toxicity	Repr.	2	H361

Discovery and Applications

Mosapride citrate, a prokinetic agent, was developed in Japan during the late 1980s and early 1990s by Dainippon Sumitomo Pharma. Researchers aimed to create a compound that could effectively treat gastrointestinal disorders by enhancing gastrointestinal motility without causing significant adverse effects. Mosapride acts as a selective 5-HT4 receptor agonist, stimulating serotonin receptors in the gastrointestinal tract to enhance motility. Its discovery was significant as it provided an alternative to existing prokinetic drugs with better safety and efficacy profiles.

Mosapride citrate is commonly prescribed for the treatment of gastroesophageal reflux disease (GERD). GERD is a chronic condition characterized by the backward flow of stomach contents into the esophagus, causing symptoms such as heartburn and acid regurgitation. Mosapride enhances esophageal and gastric motility, facilitating faster gastric emptying and reducing the incidence of reflux. Its selective action on 5-HT4 receptors ensures fewer side effects compared to other prokinetic agents.

Functional dyspepsia is a condition marked by chronic or recurrent pain and discomfort in the upper abdomen. It is often associated with delayed gastric emptying and impaired gastric motility. Mosapride citrate helps to manage functional dyspepsia by promoting gastric emptying and improving gastrointestinal motility.

Irritable bowel syndrome (IBS) is a common gastrointestinal disorder characterized by abdominal pain, bloating, and altered bowel habits. For IBS patients with predominant constipation (IBS-C), mosapride citrate can be beneficial. By stimulating 5-HT4 receptors, mosapride enhances intestinal transit, helping to relieve constipation and associated symptoms.

Postoperative ileus is a temporary impairment of bowel motility following abdominal surgery, leading to discomfort, bloating, and delayed recovery. Mosapride citrate can be used to prevent and treat postoperative ileus by stimulating gastrointestinal motility. Enhancing bowel movements and promoting faster gastric emptying helps to reduce the duration of ileus and accelerates the recovery process. This application is particularly valuable in surgical settings.

Diabetic gastroparesis is a condition where delayed gastric emptying occurs due to diabetes-related nerve damage. This condition can cause nausea, vomiting, and poor glycemic control. Mosapride citrate, by enhancing gastric motility, helps to manage the symptoms of diabetic gastroparesis.

References

1998. The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease. Alimentary Pharmacology & Therapeutics.
DOI: 10.1046/j.1365-2036.1998.00268.x

2023. Prokinetics for the treatment of functional dyspepsia: an updated systematic review and network meta-analysis. BMC Gastroenterology.
DOI: 10.1186/s12876-023-03014-9

2024. A randomized controlled study to assess the effect of mosapride citrate on intestinal recovery following gastrectomy. Scientific Reports.
DOI: 10.1038/s41598-024-57870-w